Metronidazole Braun (Metronidazole)

Metronidazole is taken up by anaerobic microorganisms and reduced by intracellular electron‑transfer proteins. This reduction creates reactive nitro radicals that bind to DNA, causing strand breakage and inhibition of nucleic acid synthesis, which ultimately leads to cell death. The activation occurs preferentially in low‑oxygen environments, sparing most aerobic human cells.

The specific dose and duration of Metronidazole Braun are determined by the prescribing clinician based on the infection type, severity, patient weight, renal and hepatic function, and local treatment guidelines. Healthcare professionals select the appropriate regimen and adjust it as needed for individual patient factors.

Safety data for Metronidazole Braun during pregnancy and lactation are limited. The drug is classified as Category ? in many regions, indicating that potential benefits must be weighed against possible risks to the fetus or infant. Clinicians should consider alternative therapies when possible and discuss any concerns with the patient.

To place an order, visit the product page on gnhindia.com, enter the required quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if required), and necessary import documentation.

Metronidazole is a nitroimidazole that offers rapid bactericidal activity against obligate anaerobes and certain protozoa, often with a narrower spectrum than broad‑spectrum agents such as carbapenems. It is generally well‑tolerated, inexpensive, and available in IV form, making it a first‑line choice for many intra‑abdominal and gynecologic anaerobic infections.

Metronidazole Braun should be stored at 2‑8 °C in a refrigerator, protected from light. The vial must not be frozen or shaken vigorously. Before use, inspect the solution for particulate matter or discoloration and discard if any abnormalities are observed.

Metronidazole Braun is given by intravenous infusion under the supervision of qualified healthcare personnel. The infusion rate and dilution volume are determined by the prescriber and pharmacy staff, typically using compatible IV fluids. Administration should follow aseptic technique and institutional protocols for IV drug delivery.

Serious adverse events include seizures, peripheral neuropathy, severe allergic reactions such as anaphylaxis or Stevens‑Johnson syndrome, hepatic toxicity, and hematologic abnormalities like neutropenia. Patients should be monitored for neurological symptoms, skin reactions, and liver function changes, especially during prolonged therapy.

Metronidazole Braun is contraindicated in individuals with a known hypersensitivity to metronidazole or other nitroimidazole compounds. Caution is also advised for patients with severe hepatic or renal impairment, those receiving disulfiram, and patients for whom alternative therapies are more appropriate due to pregnancy or lactation concerns.